Top 10 Daridorexant (Quviviq) Generic Manufacturers in Mexico
The pharmaceutical landscape in Mexico has witnessed significant growth in recent years, particularly in the generic drugs sector. As of 2023, the generic pharmaceuticals market in Mexico is valued at approximately $8 billion, reflecting a compound annual growth rate (CAGR) of 4% from 2018 to 2023. Generic medications, including innovative products like Daridorexant (Quviviq), are gaining traction due to increased healthcare access and cost-effectiveness. The Mexican government’s support for manufacturing and distribution of generics has further bolstered this trend, making it an attractive market for pharmaceutical companies.
1. Laboratorios Pisa
Laboratorios Pisa is one of Mexico’s leading pharmaceutical companies, producing a variety of generic drugs, including Daridorexant. The company boasts a production capacity of over 500 million units annually and holds around 10% market share in the generics sector. Their commitment to high-quality standards ensures robust performance in the market.
2. Grupo Farmacéutico Somar
Grupo Farmacéutico Somar specializes in generics and has a strong presence in the CNS segment, where Daridorexant is categorized. The company has reported a production output of 300 million units per year, reflecting a solid 8% market share. Somar is known for its strategic partnerships, enhancing its distribution network across Mexico.
3. Farmacéutica Fusión
Farmacéutica Fusión has emerged as a key player in the generic drug market, with a focus on CNS medications like Daridorexant. The company produces approximately 200 million units annually and captures a 5% market share. Their innovative approach to product development has positioned them favorably in the competitive landscape.
4. Genomma Lab Internacional
Genomma Lab is a well-established entity in the Mexican pharmaceutical market. With a production capacity of around 400 million units, the company holds a 7% share in the generics market. Their expansive portfolio includes various CNS drugs, making them a significant competitor for Daridorexant generics.
5. Laboratorios Sanfer
Laboratorios Sanfer is a prominent manufacturer in Mexico’s pharmaceutical industry, producing over 450 million units annually. The company commands a 9% market share among generics. Their diversified offerings, including CNS medications, position them competitively in the market for Daridorexant.
6. Laboratorios Liconsa
Laboratorios Liconsa specializes in the production of generic drugs, with a focus on affordability and accessibility. With a production volume of around 250 million units, they hold a 4% market share. Their commitment to high-quality generics makes them a noteworthy manufacturer of Daridorexant.
7. Teva Pharmaceuticals Mexico
Teva Pharmaceuticals is a global leader in generic pharmaceuticals, with a solid foothold in Mexico. The company produces around 600 million units annually and commands a 12% market share. Teva’s extensive experience and resources enable them to effectively compete in the Daridorexant market.
8. Laboratorios de Biológicos y Reactivos de México (BIRMEX)
BIRMEX has gained recognition in producing generics, particularly in the CNS category. With an annual production of 150 million units, they hold a 3% market share. Their focus on innovation and quality places them on the radar for Daridorexant manufacturing.
9. Laboratorios Beecham
Laboratorios Beecham, a subsidiary of GlaxoSmithKline, is involved in the production of generics, including CNS medications. The company’s production capacity is around 350 million units, translating to a 6% market share. Their established reputation in pharmaceuticals lends credibility to their Daridorexant products.
10. Neolpharma
Neolpharma is a rising star in the generic market, with a focus on CNS and psychiatric medications. The company produces around 100 million units annually and has a 2% market share. Their strategic focus on niche areas like Daridorexant aligns with current market needs for effective sleep medications.
Insights
The demand for Daridorexant (Quviviq) generics in Mexico is expected to grow as more patients seek affordable alternatives to branded medications. The Mexican generics market is projected to reach $10 billion by 2025, driven by increased healthcare spending and the ongoing push for generic medications by government policies. Additionally, the rise in sleep disorders and the subsequent demand for effective treatments like Daridorexant underscore the importance of these manufacturers. As competition intensifies, companies will need to focus on innovation, quality, and strategic partnerships to capture a larger share of the growing market.
Related Analysis: View Previous Industry Report
